Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment
The cellular and molecular mechanisms underlying tumor cell PD-L1 (tPD-L1) function in
tumor immune evasion are incompletely understood. We report here that tPD-L1 does not …
tumor immune evasion are incompletely understood. We report here that tPD-L1 does not …
Application of cyclodextrin for Cancer Immunotherapy
X Wei, CY Yu, H Wei - Molecules, 2023 - mdpi.com
Tumor immunotherapy, compared with other treatment strategies, has the notable
advantage of a long-term therapeutic effect for preventing metastasis and the recurrence of …
advantage of a long-term therapeutic effect for preventing metastasis and the recurrence of …
Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
TA Telli, G Bregni, M Vanhooren, RS Conde… - Cancer Treatment …, 2022 - Elsevier
Immune checkpoint inhibitors (ICIs) have marked a new era of cancer treatment, showing
remarkable efficacy in a wide range of solid malignancies. In colorectal cancer (CRC) …
remarkable efficacy in a wide range of solid malignancies. In colorectal cancer (CRC) …
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer
Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies.
CD39 expression is a promising surrogate of tumor-reactive CD8+ T cells. Here, we …
CD39 expression is a promising surrogate of tumor-reactive CD8+ T cells. Here, we …
[HTML][HTML] Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity
A Chow, S Schad, MD Green, MD Hellmann, V Allaj… - Cancer Cell, 2021 - cell.com
Immune checkpoint blockade (ICB) has been a remarkable clinical advance for cancer;
however, the majority of patients do not respond to ICB therapy. We show that metastatic …
however, the majority of patients do not respond to ICB therapy. We show that metastatic …
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
Background & Aims Programmed cell death-1 (PD-1) inhibitor treatment can cause
hyperprogressive disease (HPD), but the incidence, outcome, and predictive factors of HPD …
hyperprogressive disease (HPD), but the incidence, outcome, and predictive factors of HPD …
Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis
F Wang, MM He, YC Yao, X Zhao, ZQ Wang, Y Jin… - Cell Reports …, 2021 - cell.com
This is a phase Ib/II study of regorafenib plus toripalimab for colorectal cancer. The objective
response rate (ORR) is 15.2% and the disease control rate is 36.4% in evaluable patients …
response rate (ORR) is 15.2% and the disease control rate is 36.4% in evaluable patients …
CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis
Y Zhang, G Liu, Q Zeng, W Wu, K Lei, C Zhang, M Tang… - Cancer Cell, 2024 - cell.com
Tertiary lymphoid structures (TLSs) are associated with enhanced immunity in tumors.
However, their formation and functions in colorectal cancer liver metastasis (CRLM) remain …
However, their formation and functions in colorectal cancer liver metastasis (CRLM) remain …
Recruiting T cells in cancer immunotherapy
Immunotherapies that enhance the ability of the immune system to target cancer cells have
proven effective in a variety of tumor types, yet clinical responses vary across patients and …
proven effective in a variety of tumor types, yet clinical responses vary across patients and …
Solid stress impairs lymphocyte infiltration into lymph-node metastases
Strong and durable anticancer immune responses are associated with the generation of
activated cancer-specific T cells in the draining lymph nodes. However, cancer cells can …
activated cancer-specific T cells in the draining lymph nodes. However, cancer cells can …